MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3 Retraction in /10.3892/ijo.2024.5670

Zheng,Xin-Min; Zhang,Peng; Liu,Man-Hua; Chen,Ping; Zhang,Wei-Bing

doi:10.3892/ijo.2018.4647

MicroRNA-30e inhibits adhesion, migration, invasion and cell cycle progression of prostate cancer cells via inhibition of the activation of the MAPK signaling pathway by downregulating CHRM3

Retraction in: /10.3892/ijo.2024.5670

Authors:
- Xin-Min Zheng
- Peng Zhang
- Man-Hua Liu
- Ping Chen
- Wei-Bing Zhang
View Affiliations

Affiliations: Department of Urology, Zhongnan Hospital of WuHan University, Wuhan, Hubei 430071, P.R. China, The Second Department of Surgery, Jingan People's Hospital, Jingan, Jiangxi 330600, P.R. China
Published online on: November 26, 2018 https://doi.org/10.3892/ijo.2018.4647
Pages: 443-454
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate cancer (PCa) testing is currently based on measurement of serum prostate‑specific antigen levels and digital rectal examination, which are limited by a low predictive value and the adverse effects associated with overdiagnosis and overtreatment. Recent studies have reported that the abnormal expression of microRNAs (miRNAs) is associated with the mechanism underlying the development of PCa. Thus, the aim of the present study was to investigate the effects of miR‑30e and its target gene, M3 muscarinic acetylcholine receptor (CHRM3), on the adhesion, migration, invasion and cell cycle distribution of PCa cells via the mitogen‑activated protein kinase (MAPK) signaling pathway. The differentially expressed genes were screened in the Gene Expression Omnibus database from a gene expression microarray (GSE55945) of PCa. PCa tissues and adjacent tissues were collected from patients with PCa. The PC‑3 and DU145 human PCa cell lines were treated with activator, inhibitor and siRNAs. The effects of miR‑30e on cell adhesion, migration, invasion and cell cycle distribution with the involvement of CHRM3 and the MAPK signaling pathway were investigated. The bioinformatics results demonstrated that the CHRM3 gene and the MAKP signaling pathway were involved in the progression of PCa, and has‑miR‑30e was selected for further study. The levels of miR‑30e were significantly downregulated, while the levels of CHRM3 were obviously upregulated in PCa. CHRM3 was verified as a target gene of miR‑30e. Upregulation of miR‑30e and downregulation of CHRM3 decreased the levels of p‑P38, p‑extracellular signal‑regulated kinase, p‑c‑Jun N‑terminal kinase, p‑c‑fos and p‑c‑JUN, cell adhesion, migration and invasion ability, and the number of cells in the S phase, while they increased the number of cells in the G0 and G1 phases. The findings of the present study suggest that miR‑30e inhibited the adhesion, migration, invasion and cell cycle entry of PCa cells by suppressing the activation of the MAPK signaling pathway and inhibiting CHRM3 expression. Thus, miR‑30e may serve as a candidate target for the treatment of PCa.

View Figures

View References

1	Quinn DI, Shore ND, Egawa S, Gerritsen WR and Fizazi K: Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 33:245–260. 2015. View Article : Google Scholar
2	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010. View Article : Google Scholar
3	Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC and Ellinger J: Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 77(1265): e1269–1216. 2011. View Article : Google Scholar
4	Wen X, Deng FM and Wang J: MicroRNAs as predictive biomarkers and therapeutic targets in prostate cancer. Am J Clin Exp Urol. 2:219–230. 2014.
5	Lynch SM, McKenna MM, Walsh CP and McKenna DJ: miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate. 76:637–648. 2016. View Article : Google Scholar
6	Egan SM, Karasik E, Ellis L and Gollnick SO: miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth. Oncotarget. 8:67626–67638. 2017. View Article : Google Scholar
7	Wang N, Yao M, Xu J, Quan Y, Zhang K, Yang R and Gao WQ: Autocrine activation of CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of Akt. Clin Cancer Res. 21:4676–4685. 2015. View Article : Google Scholar
8	Ling MT, Wang X, Ouyang XS, Lee TK, Fan TY, Xu K, Tsao SW and Wong YC: Activation of MAPK signaling pathway is essential for Id-1 induced serum independent prostate cancer cell growth. Oncogene. 21:8498–8505. 2002. View Article : Google Scholar
9	Aghaee-Bakhtiari SH, Arefian E, Naderi M, Noorbakhsh F, Nodouzi V, Asgari M, Fard-Esfahani P, Mahdian R and Soleimani M: MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: Computational and in vitro approaches. Tumour Biol. 36:4203–4212. 2015. View Article : Google Scholar
10	Pértega-Gomes N, Vizcaíno JR, Miranda-Gonçalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, et al: Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer. 11:3122011. View Article : Google Scholar
11	Wu Q and Parry G: Hepsin and prostate cancer. Front Biosci. 12:5052–5059. 2007. View Article : Google Scholar
12	Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 412:822–826. 2001. View Article : Google Scholar
13	Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA and Milbrandt J: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61:5692–5696. 2001.
14	Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA and Weissleder R: Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res. 68:2286–2291. 2008. View Article : Google Scholar
15	Mannan Baig A, Khan NA, Effendi V, Rana Z, Ahmad HR and Abbas F: Differential receptor dependencies: Expression and significance of muscarinic M1 receptors in the biology of prostate cancer. Anticancer Drugs. 28:75–87. 2017. View Article : Google Scholar
16	Guo L, Liu Y, Ding Z, Sun W and Yuan M: Signal transduction by M3 muscarinic acetylcholine receptor in prostate cancer. Oncol Lett. 11:385–392. 2016. View Article : Google Scholar : PubMed/NCBI
17	Petersdorf RG: A matter of integrity. Acad Med. 64:119–123. 1989. View Article : Google Scholar
18	Caromile LA and Shapiro LH: PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. Mol Cell Oncol. 4:e13211682017. View Article : Google Scholar
19	Sun P, Sun X, Zhao W, Ren M, Zhang C, Wang Z and Xu W: Lemur tyrosine kinase-3 suppresses growth of prostate cancer via the AKT and MAPK signaling pathways. Cell Physiol Biochem. 42:2582–2592. 2017. View Article : Google Scholar : PubMed/NCBI
20	Zhang J, Wang X, Wang Y, Peng R, Lin Z, Wang Y, Hu B, Wang J and Shi G: Low expression of microRNA-30c promotes prostate cancer cells invasion involved in downregulation of KRAS protein. Oncol Lett. 14:363–368. 2017. View Article : Google Scholar
21	Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, Killary AM, Liu CG, Liang H, Mathy C, et al: Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett. 356:404–409. 2015. View Article : Google Scholar
22	Xu G, Cai J, Wang L, Jiang L, Huang J, Hu R and Ding F: MicroRNA-30e5p suppresses non-small cell lung cancer tumorigenesis by regulating USP22-mediated Sirt1/JAK/STAT3 signaling. Exp Cell Res. 362:268–278. 2018. View Article : Google Scholar
23	Liu MM, Li Z, Han XD, Shi JH, Tu DY, Song W, Zhang J, Qiu XL, Ren Y and Zhen LL: MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in breast cancer. Sci Rep. 7:159292017. View Article : Google Scholar :
24	Leão R, Domingos C, Figueiredo A, Hamilton R, Tabori U and Castelo-Branco P: Cancer stem cells in prostate cancer: Implications for targeted therapy. Urol Int. 99:125–136. 2017. View Article : Google Scholar
25	Leite KR, Reis ST, Viana N, Morais DR, Moura CM, Silva IA, Pontes J Jr, Katz B and Srougi M: Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J Cancer. 6:292–301. 2015. View Article : Google Scholar
26	Tang X, Tang X, Gal J, Kyprianou N, Zhu H and Tang G: Detection of microRNAs in prostate cancer cells by microRNA array. Methods Mol Biol. 732:69–88. 2011. View Article : Google Scholar
27	Park EC, Kim G, Jung J, Wang K, Lee S, Jeon SS, Lee ZW, Kim SI, Kim S, Oh YT, et al: Differential expression of microRNAs in patients with glioblastoma after concomitant chemoradiotherapy. OMICS. 17:259–268. 2013. View Article : Google Scholar : PubMed/NCBI
28	Qin X, Li C, Guo T, Chen J, Wang HT, Wang YT, Xiao YS, Li J, Liu P, Liu ZS, et al: Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e5p/MAPK/NFAT5 pathway. J Exp Clin Cancer Res. 36:1482017. View Article : Google Scholar
29	Kim WT and Kim WJ: MicroRNAs in prostate cancer. Prostate Int. 1:3–9. 2013. View Article : Google Scholar : PubMed/NCBI
30	Sayed D and Abdellatif M: MicroRNAs in development and disease. Physiol Rev. 91:827–887. 2011. View Article : Google Scholar
31	Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, Toren A, Shomron N, Raanani P, Shpilberg O and Granot G: MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 356:597–605. 2015. View Article : Google Scholar
32	Zhao X, Zhou Y, Chen YU and Yu F: miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2. Oncol Lett. 11:4245–4251. 2016. View Article : Google Scholar
33	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
34	da Silva HB, Amaral EP, Nolasco EL, de Victo NC, Atique R, Jank CC, Anschau V, Zerbini LF and Correa RG: Dissecting major signaling pathways throughout the development of prostate cancer. Prostate Cancer. 2013.920612:2013.
35	Fu X, Shen Y, Wang W and Li X: MiR-30a-5p ameliorates spinal cord injury-induced inflammatory responses and oxidative stress by targeting Neurod 1 through MAPK/ERK signalling. Clin Exp Pharmacol Physiol. 45:68–74. 2018. View Article : Google Scholar
36	Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A, et al: Cancer Genome Atlas Research N: The molecular taxonomy of primary prostate cancer. Cell. 163:1011–1025. 2015. View Article : Google Scholar
37	Lee OK, Cha HJ, Lee MJ, Lim KM, Jung JW, Ahn KJ, An IS, An S and Bae S: Implication of microRNA regulation in para-phenylenediamine-induced cell death and senescence in normal human hair dermal papilla cells. Mol Med Rep. 12:921–936. 2015. View Article : Google Scholar : PubMed/NCBI
38	Ling XH, Han ZD, Xia D, He HC, Jiang FN, Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014. View Article : Google Scholar
39	Huang YQ, Ling XH, Yuan RQ, Chen ZY, Yang SB, Huang HX, Zhong WD and Qiu SP: miR-30c suppresses prostate cancer survival by targeting the ASF/SF2 splicing factor oncoprotein. Mol Med Rep. 16:2431–2438. 2017. View Article : Google Scholar
40	Yang Q, Sun M, Chen Y, Lu Y, Ye Y, Song H, Xu X, Shi S and Wang J: Triptolide protects podocytes from TGF-β-induced injury by preventing miR-30 downregulation. Am J Transl Res. 9:5150–5159. 2017.